Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Thomas B. Powles, James W.F. Catto, Matthew D. Galsky et al. · New England Journal of Medicine · 2024
BACKGROUND: Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes. METHODS: In this phase 3, open-label, randomized trial, we assigned, in a 1:1 ratio, cisplatin-eligible patients with muscle-invasive bladder cancer to receive neoadjuvant durvalumab plus gemcitabine-cisplatin every 3 weeks for four cycles, followed by radical cystectomy and adjuvant durvalumab every 4 weeks for eight cycles (durvalumab group), or to receive neoadjuvant gemcitabine-cisplatin followed by radical cystectomy alone (comparison group). Event-free survival was one of two primary end points. Overall survival was the key secondary end point. RESULTS: In total, 533 patients were assigned to the durvalumab group and 530 to the comparison group. The estimated event-free survival at 24 months was 67.8% (95% confidence interval [CI], 63.6 to 71.7) in the durvalumab group and 59.8% (95% CI, 55.4 to 64.0) in the comparison group (hazard ratio for progression, recurrence, not undergoing radical cystectomy, or death from any cause, 0.68; 95% CI, 0.56 to 0.82; P<0.001 by stratified log-rank test). The estimated overall survival at 24 months was 82.2% (95% CI, 78.7 to 85.2) in the durvalumab group and 75.2% (95% CI, 71.3 to 78.8) in the comparison group (hazard ratio for death, 0.75; 95% CI, 0.59 to 0.93; P = 0.01 by stratified log-rank test). Treatment-related adverse events of grade 3 or 4 in severity occurred in 40.6% of the patients in the durvalumab group and in 40.9% of those in the comparison group; treatment-related adverse events leading to death occurred in 0.6% in each group. Radical cystectomy was performed in 88.0% of the patients in the durvalumab group and in 83.2% of those in the comparison group. CONCLUSIONS: Perioperative durvalumab plus neoadjuvant chemotherapy led to significant improvements in event-free survival and overall survival as compared with neoadjuvant chemotherapy alone. (Funded by AstraZeneca; NIAGARA ClinicalTrials.gov number, NCT03732677; EudraCT number, 2018-001811-59.).
Cited by 415 works. doi:10.1056/nejmoa2408154
Authors
- Thomas B. Powles
- James W.F. Catto
- Matthew D. Galsky
- Hikmat A Al‐Ahmadie
- Joshua J. Meeks
- Hiroyuki Nishiyama
- Toan Quang Vu
- Lorenzo Antonuzzo
- Paweł Wiechno
- Атдуев Вагиф Ахметович
- Ariel Galapo Kann
- Tae‐Hwan Kim
- Cristina Suárez
- Chao-Hsiang Chang
- Florian Roghmann
- Mustafa Özgüroğlu
- Bernhard J. Eigl
- Niara Oliveira
- Tomáš Büchler
- Moran Gadot
References
- AJCC Cancer Staging Manual. 6th ed
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
- Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- A recycling framework for the construction of Bonferroni‐based multiple tests
- Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
- Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024)
- Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder